Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
about
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaBMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesisThe chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.Combining molecular targeted agents with radiation therapy for malignant gliomasOverview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.Emerging molecular targeted therapies in the treatment of head and neck cancer.Novel targeted therapies in head and neck cancer.Targeted therapy in head and neck cancer.Emerging tyrosine kinase inhibitors for head and neck cancer.RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.
P2860
Q33514437-EEFE2B86-1980-4AD2-9EB8-7308AB1A409DQ34059649-3655CE62-BB59-40D8-8AF3-E230335831CCQ34103766-29337CAA-A934-46A4-B4A7-E72F170F92EEQ34217687-2B2EE28C-799B-4AAB-9634-6B14AF23CE39Q34781075-08DF5EE1-BCA4-495B-8D8A-84F669FE0FCEQ35553791-7C818B00-0EC0-4D4F-8206-5C988ECB4369Q36129640-C6B6E0E7-4087-4059-BCD4-E9B5A6C64A16Q36504144-900D26FB-A1C8-4373-B6C9-D5547D3BDC4FQ37099594-10740317-4745-4B10-9C28-7344D956B8C6Q37414399-817BD0C9-0DA3-4CB2-BF14-E7349769A92DQ37515438-FB548DAE-8C64-45A8-AD78-4EEDE1F277F7Q37975224-5ACBD5AE-9E74-4B60-A11C-EE64AE9FD3F9Q37988981-37FFFDF7-CE08-4E98-B1BB-F26A03DCE170Q38149327-D24C40C8-5AE1-4919-B315-078CDD2D6291Q38973621-8D4A45A7-F748-4021-868D-9F163AEDA604Q39509236-4A172249-7F02-40E8-BEF0-908F1A08780F
P2860
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@ast
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@en
type
label
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@ast
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@en
prefLabel
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@ast
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@en
P2093
P921
P1476
Dose scheduling of the dual VE ...... ead and neck tumor xenografts.
@en
P2093
Andrea L Merz
Barbara Frederick
Daniel L Gustafson
David Raben
P2888
P304
P356
10.1007/S00280-007-0460-5
P577
2007-03-29T00:00:00Z
P6179
1016271436